These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 30097754

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients.
    Girardat-Rotar L, Braun J, Puhan MA, Abraham AG, Serra AL.
    BMC Nephrol; 2017 Jul 17; 18(1):241. PubMed ID: 28716055
    [Abstract] [Full Text] [Related]

  • 43. Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patients.
    Sans L, Pascual J, Radosevic A, Quintian C, Ble M, Molina L, Mojal S, Ballarin JA, Torra R, Fernández-Llama P.
    Medicine (Baltimore); 2016 Dec 17; 95(49):e5595. PubMed ID: 27930582
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Long-term effect of coffee consumption on autosomal dominant polycystic kidneys disease progression: results from the Suisse ADPKD, a Prospective Longitudinal Cohort Study.
    Girardat-Rotar L, Puhan MA, Braun J, Serra AL.
    J Nephrol; 2018 Feb 17; 31(1):87-94. PubMed ID: 28386880
    [Abstract] [Full Text] [Related]

  • 50. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.
    Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, Arya K, Risk D, Felmlee JP, Grantham JJ, Guay-Woodford LM, Bennett WM, Klahr S, Meyers CM, Zhang X, Thompson PA, Miller JP, Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).
    Clin J Am Soc Nephrol; 2007 Jan 17; 2(1):112-20. PubMed ID: 17699395
    [Abstract] [Full Text] [Related]

  • 51. Analysis of baseline parameters in the HALT polycystic kidney disease trials.
    Torres VE, Chapman AB, Perrone RD, Bae KT, Abebe KZ, Bost JE, Miskulin DC, Steinman TI, Braun WE, Winklhofer FT, Hogan MC, Oskoui FR, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin DR, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Schrier RW, HALT PKD Study Group.
    Kidney Int; 2012 Mar 17; 81(6):577-85. PubMed ID: 22205355
    [Abstract] [Full Text] [Related]

  • 52. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease.
    Segarra-Medrano A, Martin M, Agraz I, Vilaprinyó M, Chamoun B, Jatem E, Molina M, Colàs-Campàs L, Garcia-Carrasco A, Roche S.
    Clin Kidney J; 2020 Aug 17; 13(4):607-612. PubMed ID: 32905289
    [Abstract] [Full Text] [Related]

  • 53. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.
    Dekker SEI, Verhoeven A, Soonawala D, Peters DJM, de Fijter JW, Mayboroda OA, DIPAK Consortium.
    PLoS One; 2020 Aug 17; 15(5):e0233213. PubMed ID: 32442208
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.
    Bae KT, Tao C, Feldman R, Yu ASL, Torres VE, Perrone RD, Chapman AB, Brosnahan G, Steinman TI, Braun WE, Mrug M, Bennett WM, Harris PC, Srivastava A, Landsittel DP, Abebe KZ, CRISP and HALT PKD Consortium.
    Clin J Am Soc Nephrol; 2022 Mar 17; 17(3):374-384. PubMed ID: 35217526
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
    Sekine A, Hoshino J, Fujimaru T, Suwabe T, Mizuno H, Kawada M, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Mandai S, Chiga M, Kikuchi H, Ando F, Mori T, Sohara E, Uchida S, Sawa N, Takaichi K, Ubara Y.
    Am J Nephrol; 2020 Mar 17; 51(9):745-751. PubMed ID: 32784291
    [Abstract] [Full Text] [Related]

  • 59. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H, Park HC, Oh YK, Sangadi I, Wong A, Mei C, Ecder T, Wang AY, Kao TW, Huang JW, Rangan GK, Ahn C.
    BMJ Open; 2020 Feb 06; 10(2):e034103. PubMed ID: 32034027
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.